0001193125-13-201475.txt : 20130506
0001193125-13-201475.hdr.sgml : 20130506
20130506154538
ACCESSION NUMBER: 0001193125-13-201475
CONFORMED SUBMISSION TYPE: 13F-HR
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20130331
FILED AS OF DATE: 20130506
DATE AS OF CHANGE: 20130506
EFFECTIVENESS DATE: 20130506
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: BB BIOTECH AG
CENTRAL INDEX KEY: 0000924223
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 13F-HR
SEC ACT: 1934 Act
SEC FILE NUMBER: 028-06964
FILM NUMBER: 13816025
BUSINESS ADDRESS:
STREET 1: VODERGASSE 3
STREET 2: SWITZERLAND
CITY: SCHAFFHAUSEN
STATE: V8
ZIP: CH-8300
BUSINESS PHONE: 411724 59 59
MAIL ADDRESS:
STREET 1: VODERGASSE 3
STREET 2: SWITZERLAND
CITY: SCHAFFHAUSEN
STATE: V8
ZIP: CH-8300
13F-HR
1
d532220d13fhr.txt
13F HOLDINGS REPORT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 13F
Form 13F COVER PAGE
Report for Calendar Year or Quarter Ended: March 31, 2013
Check here if Amendment [_]; Amendment Number:
This Amendment (Check only one.): [_] is a restatement.
[_] adds new holdings entries.
Institutional Investment Manager Filing this Report:
Name: BB Biotech AG
Address: Vordergasse 3
Schaffhausen Switzerland CH-8200
Form 13F File Number: 28-6964
The institutional investment manager filing this report and the person by whom
it is signed hereby represent that the person signing the report is authorized
to submit it, that all information contained herein is true, correct and
complete, and that it is understood that all required items, statements,
schedules, lists, and tables are considered integral parts of this form.
Person Signing this Report on Behalf of Reporting Manager:
Name: Pascal Schmucki
Title: SIGNING AUTHORITY
Phone: 41 (44) 267 67 00
Signature, Place, and Date of Signing: /s/ Pascal Schmucki
---------------------------------------
Schaffhausen, Switzerland, May 3, 2013
Report Type (Check only one.):
[X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager
are reported in this report.)
[_] 13F NOTICE. (Check here if no holdings reported are in this report, and all
holdings are reported by other reporting manager(s).)
[_] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this
reporting manager are reported in this report and a portion are reported by
other reporting manager(s).)
Form 13F SUMMARY PAGE
Report Summary:
Number of Other Included Managers: 3
Form 13F Information Table Entry Total: 19
-----------
Form 13F Information Table Value Total: $1,266,108
-----------
(thousands)
List of Other Included Managers:
Provide a numbered list of the name(s) and Form 13F file number(s) of all
institutional investment managers with respect to which this report is filed,
other than the manager filing this report.
No. Form 13F File Number Name
--- -------------------- --------------------
1 28-11193 Biotech Focus N.V.
2 28-11191 Biotech Invest N.V.
3 28-11189 Biotech Target N.V.
2
BB BIOTECH AG
FORM 13F INFORMATION TABLE
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
-------- -------- --------- -------- ------------------ ---------- -------- ---------------------
VOTING AUTHORITY
TITLE OF VALUE SHS OR SH/ PUT/ INVESTMENT OTHER ---------------------
NAME OF ISSUER CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE
-------------- -------- --------- -------- --------- --- ---- ---------- -------- --------- ------ ----
Achillion Pharmaceuticals Inc COM 00448Q201 14,694 1,679,340 SH DEFINED 3 1,679,340 NONE NONE
Alexion Pharmaceuticals Inc COM 015351109 66,101 717,400 SH DEFINED 2 717,400 NONE NONE
Ariad Pharmaceuticals Inc COM 04033A100 52,198 2,887,075 SH DEFINED 3 2,887,075 NONE NONE
Biomarin Pharmaceutical Inc COM 09061G101 25,982 417,310 SH DEFINED 2 417,310 NONE NONE
Celgene Corp COM 151020104 263,137 2,270,186 SH DEFINED 2 2,270,186 NONE NONE
Dendreon Corp COM 24823Q107 5,989 1,264,800 SH DEFINED 2 1,264,800 NONE NONE
Endocyte Inc COM 29269A102 29,125 2,339,345 SH DEFINED 3 2,339,345 NONE NONE
Gilead Sciences Inc COM 375558103 191,845 3,920,000 SH DEFINED 1 3,920,000 NONE NONE
Halozyme Therapeutics Inc COM 40637H109 32,552 5,646,519 SH DEFINED 3 5,646,519 NONE NONE
Idenix Pharmaceuticals Inc COM 45166R204 4,425 1,250,000 SH DEFINED 3 1,250,000 NONE NONE
Immunogen Inc COM 45253H101 55,087 3,427,934 SH DEFINED 3 3,427,934 NONE NONE
Incyte Corp COM 45337C102 124,398 5,313,870 SH DEFINED 3 5,313,870 NONE NONE
Isis Pharmaceuticals Inc COM 464330109 130,339 7,694,172 SH DEFINED 3 7,694,172 NONE NONE
Medivation, Inc COM 58501N101 58,436 1,249,706 SH DEFINED 3 1,249,706 NONE NONE
Onyx Pharmaceuticals Inc COM 683399109 48,562 546,500 SH DEFINED 2 546,500 NONE NONE
Optimer Pharmaceuticals Inc COM 68401H104 17,216 1,446,700 SH DEFINED 3 1,446,700 NONE NONE
The Medicines Co COM 584688105 32,998 987,654 SH DEFINED 2 987,654 NONE NONE
Theravance Inc COM 88338T104 20,980 888,244 SH DEFINED 3 888,244 NONE NONE
Vertex Pharmaceuticals Inc COM 92532F100 92,044 1,674,445 SH DEFINED 3 1,674,445 NONE NONE
3